Method of administration and treatment
Provided herein are formulations for topical and/or transdermal administration, and methods of using these formulations for the treatment of proliferative diseases related to cancer such as cancers and related conditions, and solid tumors. Also provided are formulations for topical and/or transdermal administration, and methods of using these formulations for melasma, gout, skin disorders, and other diseases and disorders described herein as well as methods for modulating the pH (e.g. raising) of a tissue or microenvironment proximal to a tumor, modulating pH, or improving the effectiveness of know chemotherapeutic agents, immunotherapy and the like for the prevention, treatment of cancers and related conditions described herein.
1. A method of treating a gout, comprising administering a transdermal formulation consisting of a buffering agent, wherein the transdermal formulation consisting of the buffering agent is administered to a patient having abnormal levels of uric acid crystals in one or more joints, tendons or surrounding tissue, and wherein the buffering agent reduces the levels of uric acid crystals in the one or more joints, tendons or surrounding tissue of said patient, resulting in a reduction in the symptoms of the a gout, wherein the buffering agent is sodium bicarbonate.
2. The method of claim 1 , wherein the transdermal dermal formulation is administered to a patient topically.
3. The method of claim 1 , wherein the transdermal formulation raises the pH in the vicinity of where the patient is suffering from gout.
4. The method of claim 1 , wherein the transdermal formulation reduces the level of uric acid at the site where the patient is suffering from gout.
5. The method of claim 1 , wherein the transdermal formulation reduces the effects of diseases resultant from gout.
6. The method of claim 5 , wherein the disease is osteoarthritis, rheumatoid arthritis or psoriatic arthritis.
7. The method of claim 1 , wherein the sodium bicarbonate is at a concentration from about 30% to 35% w/w of the transdermal formulation.
8. The method of claim 1 , wherein the sodium bicarbonate is at a concentration of 33% w/w of the transdermal formulation.
9. The method of claim 1 , wherein a gout is one or more of a recurrent gout attack, gouty arthritis, hyperuricaemia, gout related cardiovascular disorders (e.g. hypertension, cardiovascular disease, coronary heart disease), Lesch-Nyhan syndrome, Kelley-Seegmiller syndrome, kidney disease, kidney stones, kidney failure, joint inflammation, inflammatory joint disease, arthritis, osteoarthritis, rheumatoid arthritis and psoriatic arthritis, urolithiasis, plumbism, hyperparathyroidism, psoriasis or sarcoidosis.
10. The method of claim 1 , wherein a buffering agent penetrates the skin of the patient.
11. The method of claim 1 , wherein the transdermal formulation consists of the buffering agent in an amount between about 10%-45% w/w; a penetrant portion in an amount between about 5%-55% w/w; a detergent portion in an amount between about 1% to 15% w/w; and water in an amount between about 15% to 65% w/w.